Back-to-back failures of multiple late-phase trials have raised questions about how Novartis has deployed capital in pursuit of drugs to drive growth through the 2030s.
Novartis’ board faces investor scrutiny after M&A misfires and R&D flops Read More »
A few months after a new CEO stepped up to helm Takeda, the drugmaker will now have to prepare for another leadership change as its long-time R&D head plans his exit.
Takeda’s long-term R&D head announces exit after major pipeline reorganization Read More »
It’s another prong in the agency’s digital health modernization project, which has faced setbacks and delays.
Veterans Affairs taps Amwell for telehealth revamp Read More »
Analysts called the acquisition a good fit for Axogen but said the company’s plans to finance the deal with a public stock offering could be a point of contention for investors.
CFO Preston Wells said at a healthcare conference that the company is still working through supply issues in its peripheral vascular business and had fewer hip sales than expected so far this quarter.
Stryker stock falls on slower peripheral vascular, hip sales Read More »
The CMS released draft star ratings, including the thresholds for reaching those ratings, to plans earlier this week. The grading sheet got stricter, which doesn’t bode well for insurers, one MA expert said.
Half of Medicare Advantage stars thresholds harder to reach in 2027 Read More »
The company promoted three executives and eliminated a fourth position as part of changes intended to support its ongoing commercial transformation.
Health Catalyst has cycled through three CEOs in eight months. The data analytics company is betting its newest chief can navigate an AI pivot and revenue headwinds.
Nearly half of U.S. hospitals are now without obstetric services, according to a new report, and closures could worsen as Medicaid cuts threaten hospital finances.
Half of U.S. hospitals lack maternity wards as Medicaid cuts loom: report Read More »
With multiple drug pricing initiatives like Most Favored Nation now in force, drugmakers have to reinvent their commercial strategies to stay ahead of the fast-moving policy environment, according to a new report from Numerof & Associates.
